

Please amend the claims as follows:

2. (Amended) A method for determining whether a compound of interest affects either the adenylyl cyclase or phospholipase C pathways and therefore is an agonist or antagonist of a [Gs or Gq protein coupled] receptor which couples to both Gs and Gq proteins comprising:

- (a) providing a cell line which expresses urokinase-type plasminogen activator (u-PA);
- (b) providing an expression vector comprising a nucleotide sequence encoding for a [Gs or Gq protein coupled] receptor which couples to both Gs and Gq proteins, said receptor not normally expressed in said cell line of step (a);
- (c) introducing said expression vector into said cell line, thereby providing stably transfected cells;
- (d) contacting said stably transfected cells with said compound of interest;
- and
- (e) measuring the u-PA activity of the cell culture supernatant of said cells of step (d).

7. (Amended) A method of claim 2, wherein said [Gs or Gq protein coupled] receptor is human PTHR.

8. (Amended) A method of claim 6, wherein said [Gs or Gq protein coupled] receptor is human PTHR.